Loading...
Loading...
In a report published Monday, Piper Jaffray & Co. reiterated its Neutral rating on Sequenom
SQNM, and slightly raised its price target from $4.50 to $5.00.
Piper Jaffray noted, “Sequenom announced positive preliminary 2012 results, with revenue increasing ~59% year-over-year, implying 4Q12 revenue of ~$33M, favorable to both our $25.5M estimate and consensus of $30.1M. Management described continued momentum in its MaterniT21 business, with more than 60,000 tests accessioned during 2012, topping our 57,000 estimate and translating into ~23,000 tests delivered in 4Q12 (+28% qoq). Additionally, Sequenom announced an annualized MaterniT21 run-rate of over 120,000 tests exiting 2012. We are increasing our 4Q12 and FY13 estimates to reflect the favorable pre-announcement and MaterniT21 test run-rate, but concerns over spending required to gain market share (especially following Illumina's Verinata acquisition) keep us Neutral on SQNM shares. Maintaining our 3.1 EV/Rev multiple yields a $5.00 price target (was $4.50).”
Sequenom closed on Friday at $5.23.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in